RBC Capital raised the firm’s price target on Knight Therapeutics (KHTRF) to C$8.50 from C$8 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics Posts Record 2025 Revenue, Sets Confident 2026 Outlook
- Knight Therapeutics sees FY26 revenue C$490M-C$510M
- Knight Therapeutics reports Q4 EPS C$0.09 vs. C$0.11 last year
- Knight Therapeutics sumbits supplemental MINJUVI application to ANMAT, COFEPRIS
- Knight announces approval of additional MINJUVI indication in Brazil